Treatment and prevention of bleeding in congenital hemophilia A patients with inhibitors


      The treatment of bleeding in hemophilia A patients with persistent inhibitory antibodies to factor VIII is problematic. The current standard hemostatic agents for inhibitor patients are recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrate (APCC). These “inhibitor bypassing agents” are less reliably effective than are replacement therapies for patients without inhibitors, and there are no validated laboratory assays to monitor their efficacy. Furthermore, only single rFVIIa and APCC products are available worldwide, and their use can be complicated, albeit rarely, by thrombotic events. For all these reasons, new approaches to treat bleeding in inhibitor patients are eagerly awaited. These new approaches include replacement therapy with porcine factor VIII concentrate (currently approved for use in acquired hemophilia patients), bispecific antibodies to simulate the biologic function of factor VIII (already in use in some jurisdictions), pegylated forms of activated factor VII, and strategies targeting the natural anticoagulants TFPI and antithrombin, which create a hypercoagulable phenotype to counterbalance the hypocoagulability imposed by hemophilia.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Breen Jr, F.A.
        • Tullis J.L.
        Prothrombin concentrates in treatment of Christmas disease and allied disorders.
        JAMA. 1969; 208: 1848-1852
        • Fekete L.F.
        • Holst S.L.
        • Peetoom F.
        • DeVeber L.L.
        "Auto"-factor IX concentrate: a new therapeutic approach to the treatment of haemophilia A patients with inhibitors.
        Fourteenth Int Congr Hematol. 1972; (Sao Paulo, Brazil. p. Abst 295)
        • Abildgaard C.F.
        • Britton M.
        • Harrison J.
        Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors.
        J Pediatr (Rio J). 1976; 88: 200-205
        • Buchanan G.R.
        • Kevy S.V.
        Use of prothrombin complex concentrates in hemophiliacs with inhibitors: clinical and laboratory studies.
        Pediatrics. 1978; 62: 767-774
        • Kelly P.
        • Penner J.A.
        Antihemophilic factor inhibitors. Management with prothrombin complex concentrates.
        JAMA. 1976; 236: 2061-2064
        • Lusher J.M.
        • Shapiro S.S.
        • Palascak J.E.
        • Rao A.V.
        • Levine P.H.
        • Blatt P.M.
        Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial.
        N Engl J Med. 1980; 303: 421-425
        • Kurczynski E.M.
        • Penner J.A.
        Activated prothrombin concentrate for patients with factor VIII inhibitors.
        N Engl J Med. 1974; 291: 164-167
        • Sultan Y.
        • Brouet J.C.
        • Debre P.
        Letter: treatment of inhibitors to factor VIII with activated prothrombin concentrate.
        N Engl J Med. 1974; 291: 1087
        • Sjamsoedin L.J.
        • Heijnen L.
        • Mauser-Bunschoten E.P.
        • et al.
        The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial.
        N Engl J Med. 1981; 305: 717-721
        • Lusher J.M.
        • Blatt P.M.
        • Penner J.A.
        • et al.
        Autoplex versus proplex: a controlled, double-blind study of effectiveness in acute hemarthroses in hemophiliacs with inhibitors to factor VIII.
        Blood. 1983; 62: 1135-1138
        • Seligsohn U.
        • Kasper C.K.
        • Osterud B.
        • Rapaport S.I.
        Activated factor VII: presence in factor IX concentrates and persistence in the circulation after infusion.
        Blood. 1979; 53: 828-837
        • Hedner U.
        • Kisiel W.
        Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.
        J Clin Invest. 1983; 71: 1836-1841
        • Hagen F.S.
        • Gray C.L.
        • O’Hara P.
        • et al.
        Characterization of a cDNA coding for human factor VII.
        Proc Natl Acad Sci U S A. 1986; 83: 2412-2416
        • Brinkhous K.M.
        • Hedner U.
        • Garris J.B.
        • Diness V.
        • Read M.S.
        Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease.
        Proc Natl Acad Sci U S A. 1989; 86: 1382-1386
        • Hedner U.
        • Glazer S.
        • Pingel K.
        • et al.
        Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy.
        Lancet. 1988; 2: 1193
        • Macik B.G.
        • Hohneker J.
        • Roberts H.R.
        • Griffin A.M.
        Use of recombinant activated factor VII for treatment of a retropharyngeal hemorrhage in a hemophilic patient with a high titer inhibitor.
        Am J Hematol. 1989; 32: 232-234
        • Hedner U.
        Factor VIIa in the treatment of haemophilia.
        Blood Coagul Fibrinolysis. 1990; 1: 307-317
        • Lindley C.M.
        • Sawyer W.T.
        • Macik B.G.
        • et al.
        Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
        Clin Pharmacol Ther. 1994; 55: 638-648
        • Hedner U.
        • Kristensen H.I.
        • Berntorp E.
        • Ljung R.
        • Petrini P.
        • Tengborn L.
        Pharmacokinetics of rFVIIa in children.
        Haemophilia. 1998; 4: 244a
        • Key N.S.
        • Aledort L.M.
        • Beardsley D.
        • et al.
        Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
        Thromb Haemost. 1998; 80: 912-918
        • Young G.
        • Cooper D.L.
        • Gut R.Z.
        Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
        Haemophilia. 2012; 18: 990-996
        • Kenet G.
        • Lubetsky A.
        • Luboshitz J.
        • Martinowitz U.
        Bolus megadose of recombinant factor VIIa.
        J Thromb Haemost. 2003; 1: 450-455
        • Parameswaran R.
        • Shapiro A.D.
        • Gill J.C.
        • Kessler C.M.
        Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry.
        Haemophilia. 2005; 11: 100-106
        • Konkle B.A.
        • Ebbesen L.S.
        • Erhardtsen E.
        • et al.
        Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors.
        J Thromb Haemost. 2007; 5: 1904-1913
        • Manco-Johnson M.J.
        • Abshire T.C.
        • Shapiro A.D.
        • et al.
        Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.
        N Engl J Med. 2007; 357: 535-544
        • Manco-Johnson M.J.
        • Lundin B.
        • Funk S.
        • et al.
        Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
        J Thromb Haemost. 2017; 15: 2115-2124
        • Shapiro A.D.
        • Gilchrist G.S.
        • Hoots W.K.
        • Cooper H.A.
        • Gastineau D.A.
        Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery.
        Thromb Haemost. 1998; 80: 773-778
        • Valentino L.A.
        • Cooper D.L.
        • Goldstein B.
        Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
        Haemophilia. 2011; 17: 579-589
        • Castaman G.
        The role of recombinant activated factor VII in the haematological management of elective orthopaedic surgery in haemophilia A patients with inhibitors.
        Blood Trans. 2017; : 1-9
        • Giangrande P.L.
        • Wilde J.T.
        • Madan B.
        • et al.
        Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven] in elective orthopaedic surgery in haemophilic patients with inhibitors.
        Haemophilia. 2009; 15: 501-508
        • Ludlam C.A.
        • Smith M.P.
        • Morfini M.
        • Gringeri A.
        • Santagostino E.
        • Savidge G.F.
        A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation.
        Br J Haematol. 2003; 120: 808-813
        • Aledort L.M.
        Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.
        J Thromb Haemost. 2004; 2: 1700-1708
        • Abshire T.
        • Kenet G.
        Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors.
        Haemophilia. 2008; 14: 898-902
        • Hilgartner M.W.
        • Knatterud G.L.
        The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors.
        Blood. 1983; 61: 36-40
        • Brackmann H.H.
        • Gormsen J.
        Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder.
        Lancet. 1977; 2: 933
        • Brackmann H.H.
        • Oldenburg J.
        • Schwaab R.
        Immune tolerance for the treatment of factor VIII inhibitors--twenty years’’ Bonn protocol’.
        Vox Sang. 1996; 70: 30-35
        • Leissinger C.
        • Gringeri A.
        • Antmen B.
        • et al.
        Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.
        N Engl J Med. 2011; 365: 1684-1692
        • Antunes S.V.
        • Tangada S.
        • Stasyshyn O.
        • et al.
        Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
        Haemophilia. 2014; 20: 65-72
        • Tjonnfjord G.E.
        • Brinch L.
        • Gedde-Dahl T.
        • Brosstad F.R.
        Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX.
        Haemophilia. 2004; 10: 174-178
        • Lauroua P.
        • Ferrer A.M.
        • Guerin V.
        Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors.
        Haemophilia. 2009; 15: 1300-1307
        • Rangarajan S.
        • Austin S.
        • Goddard N.J.
        • et al.
        Consensus recommendations for the use of FEIBA((R)) in haemophilia A patients with inhibitors undergoing elective orthopaedic and non-orthopaedic surgery.
        Haemophilia. 2013; 19: 294-303
        • Rota M.
        • Cortesi P.A.
        • Crea R.
        • Gringeri A.
        • Mantovani L.G.
        Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data.
        Blood Adv. 2017; 1: 2637-2642
        • Luu H.
        • Ewenstein B.
        FEIBA safety profile in multiple modes of clinical and home-therapy application.
        Haemophilia. 2004; 10: 10-16
        • Negrier C.
        • Goudemand J.
        • Sultan Y.
        • Bertrand M.
        • Rothschild C.
        • Lauroua P.
        Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors.
        Thromb Haemost. 1997; 77: 1113-1119
        • Holmstrom M.
        • Tran H.T.
        • Holme P.A.
        Combined treatment with APCC (FEIBA((R))) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A - a two-centre experience.
        Haemophilia. 2012; 18: 544-549
        • Tran H.T.
        • Sorensen B.
        • Rea C.J.
        • et al.
        Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors.
        Haemophilia. 2014; 20: 369-375
        • Valentino L.A.
        • Holme P.A.
        Should anti-inhibitor coagulant complex and tranexamic acid be used concomitantly?.
        Haemophilia. 2015; 21: 709-714
        • Treur M.J.
        • McCracken F.
        • Heeg B.
        • et al.
        Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.
        Haemophilia. 2009; 15: 420-436
        • Bonnet P.O.
        • Yoon B.S.
        • Wong W.Y.
        • Boswell K.
        • Ewenstein B.M.
        Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries.
        Haemophilia. 2009; 15: 1083-1089
        • Astermark J.
        • Donfield S.M.
        • DiMichele D.M.
        • et al.
        A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
        Blood. 2007; 109: 546-551
        • Schneiderman J.
        • Nugent D.J.
        • Young G.
        Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.
        Haemophilia. 2004; 10: 347-351
        • Gringeri A.
        • Fischer K.
        • Karafoulidou A.
        • Klamroth R.
        • Lopez-Fernandez M.F.
        • Mancuso E.
        Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.
        Haemophilia. 2011; 17: 630-635
        • Robbins D.
        • Kulkarni R.
        • Gera R.
        • Scott-Emuakpor A.B.
        • Bosma K.
        • Penner J.A.
        Successful treatment of high titer inhibitors in mild hemophilia a with avoidance of factor VIII and immunosuppressive therapy.
        Am J Hematol. 2001; 68: 184-188
        • Boughton B.J.
        • Payne A.
        • Serman A.
        • Owen C.
        Elective surgery in a haemophilic patient with high titre inhibitors: use of extracorporeal protein A immunoadsorption.
        J Clin Pathol. 1990; 43: 172
        • Habermann B.
        • Hochmuth K.
        • Hovy L.
        • Scharrer I.
        • Kurth A.H.
        Management of haemophilic patients with inhibitors in major orthopaedic surgery by immunadsorption, substitution of factor VIII and recombinant factor VIIa (NovoSeven): a single centre experience.
        Haemophilia. 2004; 10: 705-712
        • Kernoff P.B.A.
        • Thomas N.D.
        • Lilley P.A.
        • Matthews K.B.
        • Goldman E.
        • Tuddenham E.G.D.
        Clinical experience with polyelectrolyte-fractionated porcine factor VIII concentrate in the treatment of hemophiliacs with antibodies to factor VIII.
        Blood. 1984; 63: 31-41
        • Brettler D.B.
        • Forsberg A.D.
        • Levine P.H.
        • et al.
        The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII.
        Arch Intern Med. 1989; 149: 1381-1385
        • Lozier J.N.
        • Santagostino E.
        • Kasper C.K.
        • Teitel J.M.
        • Hay C.R.M.
        Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
        SeminHematol. 1993; 30: 10-21
        • Kruse-Jarres R.
        • St-Louis J.
        • Greist A.
        • et al.
        Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A.
        Haemophilia. 2015; 21: 162-170
        • Mahlangu J.N.
        • Andreeva T.A.
        • Macfarlane D.E.
        • Walsh C.
        • Key N.S.
        Recombinant B-domain-deleted porcine sequence factor VIII (r-pFVIII) for the treatment of bleeding in patients with congenital haemophilia A and inhibitors.
        Haemophilia. 2017; 23: 33-41
        • Kitazawa T.
        • Igawa T.
        • Sampei Z.
        • et al.
        A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model.
        Nat Med. 2012; 18: 1570-1574
        • Lenting P.J.
        • Denis C.V.
        • OD Christophe
        Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?.
        Blood. 2017; 130: 2463-2468
        • Oldenburg J.
        • Mahlangu J.N.
        • Kim B.
        • et al.
        Emicizumab prophylaxis in hemophilia a with inhibitors.
        N Engl J Med. 2017; 377: 809-818
        • Lentz S.R.
        • Ehrenforth S.
        • Karim F.A.
        • et al.
        Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.
        J Thromb Haemost. 2014; 12: 1244-1253
        • Golor G.
        • Bensen-Kennedy D.
        • Haffner S.
        • et al.
        Safety and pharmacokinetics of a recombinant fusion protein linking coagulation factor VIIa with albumin in healthy volunteers.
        J Thromb Haemost. 2013; 11: 1977-1985
        • Ljung R.
        • Karim F.A.
        • Saxena K.
        • et al.
        40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors.
        J Thromb Haemost. 2013; 11: 1260-1268
        • Podust V.N.
        • Balan S.
        • Sim B.C.
        • et al.
        Extension of in vivo half-life of biologically active molecules by XTEN protein polymers.
        J Control Release. 2015; 240: 52-66
        • Binder L.
        • Bar-Ilan A.
        • Hoffman M.
        • Hart G.
        Mod-5014, a long-acting FVIIa-CTP, proposing a novel prophylactic treatment supporting less frequent subcutaneous or intravenous injections with a similar mechanism of action to rFVIIa: proof-of-concept in hemophilic animal models.
        Blood. 2015; 126: 4670a
        • Chowdary P.
        • Lethagen S.
        • Friedrich U.
        • et al.
        Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.
        J Thromb Haemost. 2015; 13: 743-754
        • Pasi K.J.
        • Rangarajan S.
        • Georgiev P.
        • et al.
        Targeting of antithrombin in hemophilia a or B with RNAi therapy.
        N Engl J Med. 2017; 377: 819-828
        • Waters E.K.
        • Sigh J.
        • Friedrich U.
        • Hilden I.
        • Sorensen B.B.
        Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay.
        Haemophilia. 2017; 23: 769-776
        • Polderdijk S.G.
        • Adams T.E.
        • Ivanciu L.
        • Camire R.M.
        • Baglin T.P.
        • Huntington J.A.
        Design and characterization of an APC-specific serpin for the treatment of hemophilia.
        Blood. 2017; 129: 105-113
        • Polderdijk S.G.I.
        • Baglin T.P.
        • Huntington J.A.
        Targeting activated protein C to treat hemophilia.
        Curr Opin Hematol. 2017; 24: 446-452